Under terms of the Agreement, Koru Medical will validate the Freedom Infusion System for use with the company’s drug. The drug developer is expected to begin Phase III studies by the end of 2023 for treatment of a rare genetic disease with global prevalence of roughly 10,000 that currently has no pharmaceutical treatments.

The agreement adds to KORU Medical’s previously announced collaborations with multiple biopharmaceutical companies for Phase II and Phase III studies of treatments for neurology, immunology, pulmonology, and other diseases outside of KORU’s Medical’s core subcutaneous immunoglobulin market.

“Adding a late-stage pharmaceutical collaboration is a major milestone for our Novel Therapies business as we continue to progress our relationships to help drive greater knowledge and adoption around the benefits of subcutaneous drug delivery for patients in the home. We are excited to partner with this rare disease biopharmaceutical company to bring a therapy to an area of significant unmet need where patients have few options today,” said Linda Tharby, KORU Medical’s President and CEO. “We believe drug development companies are choosing Koru’s Freedom System because of our proven experience in delivering millions of subcutaneous home infusions each year paired with our ability to rapidly customize the Freedom System for use in their development programs and a high-confidence path to commercialization.”